How to Avoid a Broken Heart References

Jan. 9, 2006 - Natural Products Industry INSIDER
"Avoiding a Broken Heart" References

1. Haffner SM et al. Comparison of the associations of apolipoprotein Band non-high-density lipoprotein cholesterol with other cardiovascular riskfactors in patients with the metabolic syndrome in the Insulin ResistanceAtherosclerosis Study. Circ. 110(17):2687-93, 2004. http://circ.ahajournals.org

2. Hu FB, Willett WC. "Optimal diets for prevention of coronary heartdisease." JAMA. 288, 20:2569-78, 2002. www.jama.com

3. Moreyra AE et al. Effect of Combining Psyllium Fiber with Simvastatinin Lowering Cholesterol. Arch Intern Med. 165,10:1161-1166, 2005.

4. Saltzman E et al. "An oat-containing hypocaloric diet reducessystolic blood pressure and improves lipid profile beyond effects of weight lossin men and women." J Nutr. 131, 5:1465-70, 2001. www.nutrition.org

5. He J et al. "Effect of dietary fiber intake on blood pressure: arandomized, double blind, placebo-controlled trial." J Hypertens.22, 1:73-80, 2004. www.jhypertension.com

6. Pins JJ et al. "Do whole-grain oat cereals reduce the need forantihypertensive medications and improve blood pressure control?" J FamPract. 51, 4:353-9, 2002. www.jfponline.com

7. Gallaher DD et al. Reduction in liver cholesterol by a beta-glucanconcentrate in rats: correlation with intestinal contents viscosity.Presented at the Experimental Biology Conference in April, 2005. www.nurtureinc.com

8. Slavin J et al. Practical dose of concentrated beta-glucans from oatsimproves blood lipid profile. Presented at the Experimental BiologyConference in April, 2005. www.nurtureinc.com

9. Biorklund M et al. Changes in serum lipids and postprandial glucose andinsulin concentrations after consumption of beverages with beta-glucans fromoats or barley: a randomised dose-controlled trial. Eur J Clin Nutr, 59,11:1272-81, 2005.

10. Belhall KM et al. Diets containing barley significantly reduce lipidsin mildly hypercholesterolemic men and women. Am J Clin Nutr. 80,5:1185-93, 2004.

11. Jerling JC et al. A systematic review of the effects of nuts on bloodlipid profiles in humans. J Nutr. 135, 9:2082-9, 2005. www.nutrition.org

12. Alper CM, Mattes RD. "Peanut consumption improves indices ofcardiovascular disease risk in healthy adults." J Am Coll Nutr. 22,2:133-41, 2003. www.am-coll-nutr.org/jacn/jacn.htm

13. Ros E et al. "A walnut diet improves endothelial function inhypercholesterolemic subjects: a randomized crossover trial." Circulation.6, 109, 13:1609-14, 2004. http://circ.ahajournals.org/

14. Tapsell LC et al. Including Walnuts in a Low-Fat/Modified-Fat DietImproves HDL Cholesterol-to-Total Cholesterol Ratios in Patients With Type 2Diabetes. Diab Care. 27, 12:2777-83, 2004.

15. Zhao G et al. "Dietary {alpha}-linolenic acid reduces inflammatoryand lipid cardiovascular risk factors in hypercholesterolemic men andwomen." J Nutr. 134, 11:2991-7, 2004. www.nutrition.org

16. Wijendran V, Hayes KC. "Dietary n-6 and n-3 fatty acid balance andcardiovascular health." Annu Rev Nutr. 24:597-615, 2004. http://nutr.annualreviews.org/

17. Ipotova OM et al. "[Biological activity of linseed oil as the sourceof omega-3 alpha-linolenic acid."] Biomed Khim. 50, 1:25-43, 2004.

18. Erkkila AT et al. "Fish intake is associated with a reducedprogression of coronary artery atherosclerosis in postmenopausal women withcoronary artery disease." Am J Clin Nutr. 80:626-32, 2004. www.ajcn.org

19. Din JN, Newby DE, Flapan AD. "Omega 3 fatty acids and cardiovasculardisease--fishing for a natural treatment." BMJ. 328:30-5, 2004. http://bmj.com

20. Dyerberg J et al. "Effects of trans- and n-3 unsaturated fatty acidson cardiovascular risk markers in healthy males. An 8 weeks dietary interventionstudy." Eur J Clin Nutr. 58, 7:1062-70, 2004. www.naturesj.com/ejcn

21. Thies F et al. "Association of n-3 polyunsaturated fatty acids withstability of atherosclerotic plaques: a randomized controlled trial." Lancet.361, 9356:477-85, 2003. www.thelancet.com

22. Ciubotaru I, Lee YS, Wander RC. "Dietary fish oil decreasesC-reactive protein, interleukin-6 and triacylglycerol to HDL-cholesterol ratioin postmenopausal women on HRT." J Nutr Biochem. 14, 9:513-21, 2003.www.elsevier.com/locate/jnutbio

23. Vanschoonbeek K et al. "Variable hypocoagulant effect of fish oilintake in humans: modulation of fibrinogen level and thrombin generation." ArteriosclerThromb Vasc Biol. 24, 9:1734-40, 2004. http://atvb.ahajournals.org

24. Woodman RJ et al. "Effects of purified eicosapentaenoic acid anddocosahexaenoic acid on platelet, fibrinolytic and vascular function inhypertensive Type II diabetic patients." Atherosclerosis. 166,1:85-93, 2003. www.elsevier.com/locate/atherosclerosis

25. Khan F et al. "The effects of dietary fatty acid supplementation onendothelial function and vascular tone in healthy subjects." CardiovascRes. 59, 4:955-62, 2003. www.elsevier.com/locate/cardiores

26. Bunea R et al. Evaluation of the effects of Neptune Krill Oil on theclinical course of hyperlipidemia. Altern Med Rev. Dec;9, 4:420-8,2004.

27. Bloedon LT, Szapary PO. "Flaxseed and cardiovascular risk." NutrRev. 62, 1:18-27, 2004. www.ilsi.org/publications/reviews.html

28. Lucas EA et al. "Flaxseed reduces plasma cholesterol andatherosclerotic lesion formation in ovariectomized Golden Syrian hamsters."Atherosclerosis. 173, 2:223-9, 2004. www.elsevier.com/locate/atherosclerosis

29. Lucas EA et al. "Flaxseed improves lipid profile without alteringbiomarkers of bone metabolism in postmenopausal women." J ClinEndocrinol Metab. 87, 4:1527-32, 2002. http://jcem.endojournals.org

30. Pitsavos C et al. Adherence to the Mediterranean diet is associatedwith total antioxidant capacity in healthy adults: the ATTICA study. AmerJ Clin Nutr. 82, 3:694-699, 2005. www.ajcn.org

31. Alarcon de la Lastra C et al. "Mediterranean diet and health:biological importance of olive oil." Curr Pharm Des. 7, 10:933-50,2001.

32. Psaltopoulou T et al. "Olive oil, the Mediterranean diet andarterial blood pressure: the Greek European Prospective Investigation intoCancer and Nutrition (EPIC) study." Am J Clin Nutr. 80, 4:1012-8,2004. www.ajcn.org

33. Perona JS et al. "Virgin olive oil reduces blood pressure inhypertensive elderly subjects." Clin Nutr. 23, 5:1113-21, 2004. www.harcourt-international.com/journals/clnu

34. Mayer B et al. "Effects of an onion-live oil maceration productcontaining essential ingredients of the Mediterranean diet on blood pressure andblood fluidity." Arzneimittelforschung. 51, 2:104-11, 2001.

35. Massaro M, De Caterina R. "Vasculoprotective effects of oleic acid:epidemiological background and direct vascular antiatherogenic properties."Nutr Metab Cardiovasc Dis. 12, 1:42-51, 2002. www.medikal.it/index_en.htm

36. Herrera MD et al. "Effects of dietary oleic-rich oils (virgin oliveand high-oleic-acid sunflower) on vascular reactivity in Wiestar-Kyoto andspontaneously hypertensive rats." Br J Nutr. 86, 3:349-57, 2001. www.cabi-publishing.org/journals/bjn

37. Ruano J et al. Phenolic content of virgin olive oil improves ischemicreactive hyperemia in hypercholesterolemic patients. J Am Coll Cardiol.46, 10:1864-8, 2005.

38. Togna GI et al. "Olive oil isochromans inhibit human plateletreactivity." J Nutr. 133, 8:2532-6, 2003. www.nutrition.org

39. Carluccio MA et al. "Olive oil and red wine antioxidant polyphenolsinhibit endothelial activation: antiatherogenic properties of Mediterranean dietphytochemicals." Arterioscler Thromb Vasc Biol. 23, 4:622-9, 2003. http://atvb.ahajournals.org

40. Shafiee M et al. "Grape and grape seed extract capacities atprotecting LDL against oxidation generated by Cu2+, AAPH or SIN-1 and atdecreasing superoxide THP-1 cell production. A comparison to other extracts orcompounds." Free Rad Res. 37, 5:573-84, 2003. www.tandf.co.uk/journals

41. van de Wiel A. "[Nutrition and health--favorable effect of wine andwine flavonoids on cardiovascular disease.]" Ned Tijdschr Geneeskd.146, 51:2466-9, 2002.

42. Waddington E, Puddey IB, Croft KD. "Red wine polyphenolic compoundsinhibit atherosclerosis in apolipoprotein E-deficient mice independently ofeffects on lipid peroxidation." Am J Clin Nutr. 79, 1:54-61, 2004. www.ajcn.org

43. Ventura P et al. "Red wine consumption prevents vascular oxidativestress induced by a high-fat meal in healthy volunteers." Int J VitamNutr Res. 74, 2:137-43, 2004.

44. Dell'Agli M, Busciala A, Bosisio E. "Vascular effects of winepolyphenols." Cardiovasc Res. 63, 4:593-602, 2004. www.elsevier.com/locate/cardiores

45. Whelan AP et al. "Effects of white and red wine on endothelialfunction in subjects with coronary artery disease." IMJ. 34,5:224-8, 2004. www.racp.edu.au/imj/index.htm

46. Bagchi D et al. "Molecule mechanisms of cardioprotection by a novelgrape seed proanthocyanidin extract." Mutat Res. 523-524:87-97,2003. www.mutationresearch.com

47. Auger C et al. "Phenolics from commercialized grape extracts preventearly atherosclerotic lesions in hamsters by mechanisms other than antioxidanteffect." J Agric Food Chem. 52, 16:5297-302, 2004. http://pubs.acs.org/journals/jafcau

48. Natella F et al. "Grape seed proanthocyanidins prevent plasmapostprandial oxidative stress in humans." J Agric Food Chem. 50,26:7720-5, 2002. http://pubs.acs.org/journals/jafcau

49. Wood RJ et al. Grape Polyphenols Exert a Cardioprotective Effect inPre- and Postmenopausal Women by Lowering Plasma Lipids and Reducing OxidativeStress. J Nutr. 135:1911-17, 2005. www.nutrition.org

50. Xia M et al. Anthocyanins Induce Cholesterol Efflux from MousePeritoneal Macrophages. J Biol Chem, 280, 44:36792-801, 2005. www.jbc.org

51. Mathur S et al. "Cocoa products decrease low density lipoproteinoxidative susceptibility but do not affect biomarkers of inflammation inhumans." J Nutr. 132, 12:3663-7, 2002. www.nutrition.org

52. Innes AJ et al. "Dark chocolate inhibits platelet aggregation inhealthy volunteers." Platelets. 14, 5:325-7, 2003.

53. Engler MB, Engler MM. "The vasculoprotective effects offlavonoid-rich cocoa and chocolate." Nutr Res. 24, 9:695-706, 2004. www.elsevier.nl/locate/nutres

54. Yang YC et al. "The protective effect of habitual tea consumption onhypertension." Arch Intern Med. 164, 14:1534-40, 2004. http://archinte.ama-assn.org

55. Vinson JA, Teufel K, Wu N. "Green and black teas inhibitatherosclerosis by lipid, antioxidant and fibrinolytic mechanisms." JAgric Food Chem. 52, 11:3661-5, 2004. http://pubs.acs.org/journals/jafcau

56. Frei B, Higdon JV. "Antioxidant activity of tea polyphenols in vivo:evidence from animal studies." J Nutr. 133, 10:3275S-84S, 2003. www.nutrition.org

57. Chyu KY et al. "Differential effects of green tea-derived catechinon developing versus established atherosclerosis in apolipoprotein E-nullmice." Circulation. 109, 20:2448-53, 2004. http://circ.ahajournals.org/

58. Juzwiak S et al. Effect of quercetin on experimental hyperlipidemiaand atherosclerosis in rabbits. Pharmacol Rep. 57, 5:604-9 ,2005.

59. Artega E et al. Phytoestrogens possess a weak antioxidant activity onlow density lipoprotein in contrast to the flavonoid quercetin in vitro inpostmenopausal women. Climacteric. 7, 4:397-403, 2004.

60. Hasler CM. "The cardiovascular effects of soy products." JCardiovasc Nurs. 16, 4:50-63, 2002.

61. Rosell MS et al. "Soy intake and blood cholesterol concentrations: across-sectional study of 1,033 pre- and postmenopausal women in the Oxford armof the European Prospective Investigation into Cancer and Nutrition." AmJ Clin Nutr. 80, 5:1391-6, 2004. www.ajcn.org

63. Adams MR et al. Soy Protein Containing Isoflavones Reduces the Size ofAtherosclerotic Plaques without Affecting Coronary Artery Reactivity in AdultMale Monkeys. J Nutr. 135:2852-6, 2005. www.nutrition.org

64. Tachibana M et al. Intake of Soy Protein Isolate Alters Hepatic GeneExpression in Rats. J Agric Food Chem, 53, 10: 4253 -4257,2005. http://pubs3.acs.org/acs/journals/toc.page?incoden=jafcau

65. Zhan S and Ho S. Meta-analysis of the effects of soy proteincontaining isoflavones on the lipid profile. Amer J Clin Nutr. 81,2:397-408, 2005. www.ajcn.org

66. Tsuda Y et al. Anti-atherogenic effect of soya and rice-proteinisolate, compared with casein, in apolipoprotein E-deficient mice. Br JNutr. 90, 1:13-20, 2003.

67. Wang Y et al. "Soy protein reduces triglyceride levels andtriglyceride fatty acid fractional synthesis rate in hypercholesterolemicsubjects." Atherosclerosis. 173, 2:269-75, 2004. www.elsevier.com/locate/atherosclerosis

68. Jenkins DJ et al. "Effects of high- and low-isoflavone soyfoods onblood lipids, oxidized LDL, homocysteine and blood pressure in hyperlipidemicmen and women." Am J Clin Nutr. 76, 2:365-72, 2002. www.ajcn.org

69. Zhuo XG, Melby MK, Watanabe S. "Soy isoflavone intake lowers serumLDL cholesterol: a meta-analysis of eight randomized controlled trials inhumans." J Nutr. 134, 9:2395-400, 2004. www.nutrition.org

70. de Kleijn MJ et al. "Dietary intake of phytoestrogens is associatedwith a favorable metabolic cardiovascular risk profile in postmenopausal U.S.women: the Framingham study." J Nutr. 132, 2:276-82, 2002. www.nutrition.org

71. van der Schouw YT et al. "Higher usual dietary intake ofphytoestrogens is associated with lower aortic stiffness in postmenopausalwomen." Arterioscler Thromb Vasc Biol. 22, 8:1316-22, 2002. http://atvb.ahajournals.org

72. Schult TM et al. "Effect of isoflavones on lipids and bone turnovermarkers in menopausal women." Maturitas. 48, 3:209-18, 2004. www.sciencedirect.com/science/journal/03785122

73. Atkinson C et al. "Modest protective effects of isoflavones from ared clover-derived dietary supplement on cardiovascular disease risk factors inperimenopausal women, and evidence of an interaction with ApoE genotype in 49-65year old women." J Nutr. 134, 7:1759-64, 2004. www.nutrition.org

74. Nestel P et al. "A biochanin-enriched isoflavone from red cloverlowers LDL cholesterol in men." Eur J Clin Nutr. 58, 3:403-8, 2004. www.naturesj.com/ejcn

75. Kurowska EM, Manthey JA. "Hypolipidemic effects and absorption ofcitrus polymethoxylated flavones in hamsters with diet-inducedhypercholesterolemia." J Agric Food Chem. 52, 10:2879-86, 2004. http://pubs.acs.org/journals/jafcau

76. Jeon SM et al. "Comparison of antioxidant effects of naringin andprobucol in cholesterol-fed rabbits." Clin Chim Acta. 317,1-2:181-90, 2002. www.sciencedirect.com/science/journal/00098981

77. Jeon SM et al. "Antioxidative activity of naringin and lovastatin inhigh cholesterol-fed rabbits." Life Sci. 69, 24:2855-66, 2001. www.sciencedirect.com/science/journal/00243205

78. Lee CH et al. "Anti-atherogenic effect of citrus flavonoids,naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 andMCP-1 in high cholesterol-fed rabbits." Biochem Biophys Res Comm.284, 3:681-8, 2001. www.sciencedirect.com/science/journal/0006291X

79. Whitman SC et al. "Nobiletin, a citrus flavonoid isolated fromtangerines, selective inhibits class A scavenger receptor-mediated metabolism ofacetylated LDL by mouse macrophages." Atherosclerosis. [in press2005] www.elsevier.com/locate/atherosclerosis

80. Kurowska EM et al. "Modulation of HepG2 cell net apolipoprotein Bsecretion by the citrus polymethoxyflavone, tangeretin." Lipids. 39,2:143-51, 2004. www.aocs.org

81. Ohtsuki K et al. "Effects of long-term administration of hesperidinand glucosyl hesperidin to spontaneously hypertensive rats." J Nutr SciVitaminol (Tokyo). 48, 5:420-2, 2002.

82. Manners GD et al. Agri Res. 53, 2:16-17, 2005. www.ars.usda.gov/is/AR

83. Pearson L et al. Microsomal Triglyceride Transfer Protein GeneExpression and ApoB Secretion Are Inhibited by Bitter Melon in HepG2 Cells. JNutr, 135, 4:702-6, 2005. www.nutrition.org

84. Aviram M et al. "Pomegranate juice flavonoids inhibit low-densitylipoprotein oxidation and cardiovascular diseases: studies in atheroscleroticmice and in humans." Drugs Exp Clin Res. 28, 2-3:49-62, 2002.

85. Aviram M et al. "Pomegranate juice consumption reduces oxidativestress, atherogenic modifications to LDL, and platelet aggregation: studies inhumans and in atherosclerotic apolipoprotein E-deficient mice." Am JClin Nutr. 71, 5:1062-76, 2000. www.ajcn.org

86. Sumner MD et al. Effects of Pomegranate Juice Consumption onMyocardial Perfusion in Patients With Coronary Heart Disease. AmerJ Cardiol. 96, 6:810-14, 2005. http://www.sciencedirect.com/science/journal/00029149

87. Tahbaz F et al. Concentrated pomegranate juice improves lipid profilesin diabetic patients with hyperlipidemia. J Med Food. 7(3):305-8,2004.

88. Aviram M et al. "Pomegranate juice consumption for 3 years bypatients with carotid artery stenosis reduces common carotid intima-mediathickness, blood pressure and LDL oxidation." Clin Nutr. 23,3:423-33, 2004. www.harcourt-international.com/journals/clnu

89. Noda Y et al. "Antioxidant activities of pomegranate fruit extractand its anthocyanidins: delphinidin, cyanidin and pelargonidin." J AgricFood Chem. 50, 1:166-71, 2002. http://pubs.acs.org/journals/jafcau

90. Tapiero H, Townsend DM, Tew KD. "The role of carotenoids in theprevention of human pathologies." Biomed Pharmacother. 58, 2:100-10,2004. www.elsevier.nl/inca/publications/store/5/0/5/8/1/0

91. Rao AV. "Lycopene, tomatoes and the prevention of coronary heartdisease." Exp Biol Med (Maywood). 227, 10:908-13, 2002.

92. Fuhrman B et al. "Lycopene synergistically inhibits LDL oxidation incombination with vitamin E, glabridin, rosmarinic acid, carnosic acid orgarlic." Antioxid Redox Signal. 2, 3:491-506, 2000.

93. Rao AV. "Lycopene, tomatoes and the prevention of coronary heartdisease." Exp Biol Med (Maywood). 227, 10:908-13, 2002. www.ebmonline.org

94. Maruyama C et al. "Effects of tomato juice consumption on plasma andlipoprotein carotenoid concentrations and the susceptibility of low densitylipoprotein to oxidative modification." J Nutr Sci Vitaminol (Tokyo).47, 3:213-21, 2001.

95. Rissanen TH et al. "Serum lycopene concentrations and carotidatherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study." AmJ Clin Nutr. 77, 1:133-8, 2003. www.ajcn.org

96. Dwyer JH et al. Oxygenated carotenoid lutein and progression of earlyatherosclerosis: the Los Angeles atherosclerosis study. Circulation.103, 24:2922-7, 2001.

97. Dwyer JH et al. "Progression of carotid intima-media thickness andplasma antioxidants: the Los Angeles Atherosclerosis Study." ArteriosclerThromb Vasc Biol. 24, 2:313-9, 2004. http://atvb.ahajournals.org

98. Iwamoto T et al. "Inhibition of low-density lipoprotein oxidation byastaxanthin." J Atheroscler Thromb. 7, 4:216-22, 2000. www.jstage.jst.go.jp/browse/jat

99. Hussein G et al. Antihypertensive potential and mechanism of action ofastaxanthin: II. Vascular reactivity and hemorheology in spontaneouslyhypertensive rats. Biol Pharm Bull. 28, 6:967-71, 2005. http://www.jstage.jst.go.jp/browse/bpb

100. Myawaki H et al. Effects of astaxanthin on human blood rheology.J Clin Therapeutics Med. 21, 4: ,2005.

101. Hellsten A et al. Alpha-tocopherol and astaxanthin decreasemacrophage infiltration, apoptosis and vulnerability in atheroma ofhyperlipidaemic rabbits. J Mol Cell Cardiol. 37, 5:969-78, 2004.

102. Carpenter KL et al. "Oral alpha-tocopherol supplementation inhibitslipid oxidation in established human atherosclerotic lesions." Free RadRes. 37, 11:1235-44, 2003. www.tandf.co.uk/journals

103. Hodis HN et al. "Alpha-tocopherol supplementation in healthyindividuals reduces low-density lipoprotein oxidation but not atherosclerosis:the Vitamin E Atherosclerosis Prevention Study (VEAPS)." Circulation.106, 12:1453-9, 2002. http://circ.ahajournals.org/

104. Inokuchi H et al. "Anti-angiogenic activity of tocotrienol." BiosciBiotechnol Biochem. 67, 7:1623-7, 2003. www.jsbba.or.jp/bbindexj.html

105. Raederstorff D et al. "Effect of either gamma-tocotrienol or atocotrienol mixture on the plasma lipid profile in hamsters." Ann NutrMetab. 46, 1:17-23, 2002. www.karger.com/anm

106. Sundram K, Sambanthamurthi R, Tan YA. "Palm fruit chemistry andnutrition." Asia Pac J Clin Nutr. 12, 3:355-62, 2003. www.healthyeatingclub.com/APJCN/ProcNutSoc/

107. Munteanu A et al. "Modulation of cell proliferation and geneexpression by alpha-tocopheryl phosphates: relevance to atherosclerosis andinflammation." Biochem Biophys Res Comm. 318:311-6, 2004. www.sciencedirect.com/science/journal/0006291X

108. Rezk BM et al. "The extraordinary antioxidant activity of vitamin Ephosphate." Biochim Biophys Acta. 1683:16-21, 2004. www.elsevier.nl/locate/bba

109. Salonen RM et al. "Six-year effect of combined vitamin C and Esupplementation on atherosclerotic progression: the Antioxidant Supplementationin Atherosclerosis Prevention (ASAP) Study." Circulation. 107,7:947-53, 2003. http://circ.ahajournals.org/

110. Nagyova A et al. "Lipid peroxidation in men after dietarysupplementation with a mixture of antioxidant nutrients." Bratisl LekListy. 105, 7-8:277-80, 2004.

http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=home&id=hj

111. Kurl S et al. "Plasma vitamin C modifies the association betweenhypertension and risk of stroke." Stroke. 33, 6:1568-73, 2002. http://stroke.ahajournals.org/

112. Kim MK et al. "Lack of long-term effect of vitamin Csupplementation on blood pressure." Hypertension. 40, 6:797-803,2002. http://hyper.ahajournals.org

113. Eskurza I et al. "Ascorbic acid does not affect large elasticartery compliance or central blood pressure in young and older men." AmJ Physiol Heart Circ Physiol. 286, 4:H1528-34, 2004.

114. Rosenfeldt F et al. "Systematic review of effect of coenzyme Q10 inphysical exercise, hypertension and heart failure." Biofactors. 18,1-4:91-100, 2003. www.iospress.nl/site/html/09516433.html

115. Houston MC. "The role of vascular biology, nutrition andnutraceuticals in the prevention and treatment of hypertension." JANA.S1:5-71, 2002. www.americanutra.com/jana.html

116. Singh RB et al. "Effect of coenzyme Q10 on experimentalatherosclerosis and chemical composition and quality of atheroma inrabbits." Atherosclerosis. 148, 2:275-82, 2000. www.elsevier.com/locate/atherosclerosis

117.Sarter B. "Coenzyme Q10 and cardiovascular disease: a review." JCardiovasc Nurs. 16, 4:9-20, 2002.

118. Rundek T et al. "Atorvastatin decreases the coenzyme Q10 level inthe blood of patients at risk for cardiovascular disease and stroke." ArchNeurol. 61:889-92, 2004. http://archneur.ama-assn.org

119.Singh RB et al. "Effect of coenzyme Q10 on risk of atherosclerosisin patients with recent myocardial infarction." Mol Cell Biochem.246, 1-2:75-82, 2003. www.wkap.nl159.

120. Thomas SR et al. "Dietary cosupplementation with vitamin E andcoenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockoutmice." Arterioscler Thromb Vasc Biol. 21, 4:585-93, 2001. http://atvb.ahajournals.org

121. Kramer K and Packer L. R-alpha-lipoic acid. Nutraceuticals inHealth and Disease Prevention. New York: Marcel Dekker, Inc.;2001:129-164. 

122. Heitzer T et al. Beneficial effects of alpha-lipoic acid and ascorbicacid on endothelium-dependent, nitric oxide-mediated vasodilation in diabeticpatients: relation to parameters of oxidative stress. Free Radic Biol Med.31, 1:53-61, 2001.

123. Midaoui AE et al. "Lipoic acid prevents hypertension, hyperglycemiaand the increase in heart mitochondrial superoxide production." Am JHypertens. 16, 3:173-9, 2003.

124. Vasdev S et al. "Salt-induced hypertension in WKY rats: preventionby alpha-lipoic acid supplementation." Mol Cell Biochem. 254,1-2:319-26, 2003. www.wkap.nl

125. Wollin SD, Jones PJ. "Alpha-lipoic acid and cardiovasculardisease." J Nutr. 133, 11:3327-30, 2003. www.nutrition.org

126. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. "Effect ofalpha-lipoic acid on lipid profile in rats fed a high-fructose diet." ExpDiabesity Res. 5, 3:195-200, 2004.

127. Noone EJ et al. The effect of dietary supplementation using isomericblends of conjugated linoleic acid on lipid metabolism in healthy humansubjects. Br J Nutr. 88, 3:243-51, 2002.

128. Lock AL et al. Butter naturally enriched in conjugated linoleic acidand vaccenic acid alters tissue fatty acids and improves the plasma lipoproteinprofile in cholesterol-fed hamsters. J Nutr. 135, 8:1934-9, 2005. www.nitrition.org

129. Kim HK et al. Dietary conjugated linoleic acid reduces lipidperoxidation by increasing oxidative stability in rats.J Nutr SciVitaminol. 51, 1:8-15, 2005.

130. Lee O, Moon J, Chung Y. "The relationship between serum seleniumlevels and lipid profiles in adult women." J Nutr Sci Vitaminol (Tokyo).49, 6:397-404, 2003.

131. Gonzalez S et al. "Serum selenium is associated with plasmahomocysteine concentrations in elderly humans." J Nutr. 134,7:1736-40, 2004. www.nutrition.org

132. Alissa EM, Eahijri SM, Fearns GA. op cit.

133. Touyz RM. "Role of magnesium in the pathogenesis ofhypertension." Mol Aspects Med. 24, 1-3:107-36, 2003. www.sciencedirect.com/science/journal/00982997

134. Feillet-Coudray C et al. "Exchangeable magnesium pool masses inspontaneously hypertensive rats." Metabolism. 52, 5:626-30, 2003. www.sciencedirect.com/science/journal/00260495

135. Haas NA et al. "Effect of increasing doses of magnesium inexperimental pulmonary hypertension after acute pulmonary embolism." IntensiveCare Med. Sept. 9, 2004. [epub ahead of print.]

136. Keller S et al. Cholesterol Metabolism Is Affected by CalciumPhosphate Supplementation in Humans. J Nutr. 135:1678-1682, 2005. www.nutrition.org

137. Tyson DA et al. "Acute effects of grape seed extract andniacin-bound chromium on cardiovascular parameters of normotensive andhypertensive rats." Res Comm Pharmacol Toxicol. 5, 1-2:91-106, 2000.

138. Ablarracin C et al. Presented at the American Heart Associationssixth Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology,2005. www.wmericanheart.og

139. Das UN. "Folic acid says NO to vascular diseases." Nutrition.19, 7-8:686-92, 2003. www.elsevier.com/locate/nut

140. Splaver A, Lamas GA, Hennekens CH. "Homocysteine and cardiovasculardisease: biological mechanisms, observational epidemiology and the need forrandomized trials." Am Heart J. 148, 1:34-40, 2004. www2.us.elsevierhealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=home&id=hj

141. Naruta E, Buko V. "Hypolipidemic effect of panthothenic acidderivatives in mice with hypothalamic obesity induced by aurothioglucose." ExpToxicol Pathol. 53, 5:393-8, 2001.

142. Osono Y et al. "The effects of pantethine on fatty liver and fatdistribution." J Atheroscler Thromb. 7, 1:55-8, 2000. www.jstage.jst.go.jp/browse/jat

143. Keenan JM, Pins JJ, First S. Results presented at the American HeartAssociation Scientific Sessions, Nov. 8, 2004.

144. Morgan JM et al. "The effects of niacin on lipoprotein subclassdistribution." Prev Cardiol. 7, 4:182-9, 2004. www.lejacq.com/preventive.cfm

145. Taylor AJ et al. "Arterial Biology for the Investigation of theTreatment Effects of Reducing Cholesterol (ARBITER) 2. A double blind,placebo-controlled study of extended-release niacin n atherosclerosisprogression in secondary prevention patients treated with statins." Circulation.Nov. 10, 2004. [epub ahead of print.] http://circ.ahajournals.org/

146. Moon YS, Kashyap ML. "Niacin extended-release/lovastatin:combination therapy for lipid disorders." Expert Opin Pharmacother.3, 12:1763-71, 2002.

147. Jones PJ et al. Plant sterols are efficacious in lowering plasma LDLand non-HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabeticpersons. Amer J Clin Nutr. 81, 6:1351-58, 2005. www.ajcn.org

148. Nestel P et al. "Cholesterol-lowering effects of plant sterolesters and non-esterified stanols in margarine, butter and low-fat foods." EurJ Clin Nutr. 55, 12:1084-90, 2001. www.naturesj.com/ejcn

149. Matvienko OA et al. "A single daily dose of soybean phytosterols inground beef decreases serum total cholesterol and LDL cholesterol in young,mildly hypercholesterolemic men." Am J Clin Nutr. 76:57-64, 2002. www.ajcn.org

150. Devaraj S, Jialal I, Vega S. "Plant sterol-fortified orange juiceeffective lowers cholesterol levels in mildly hypercholesterolemic healthyindividuals." Arterioscler Thromb Vasc Biol. 24:1-5, 2004. http://atvb.ahajournals.org

151. Jones P et al. Presented at the FASEB conference, April 2005.

152. Carr TP et al. Grain Sorghum Lipid Extract Reduces CholesterolAbsorption and Plasma Non-HDL Cholesterol Concentration in Hamsters. J.Nutr. 135:2236-2240, 2005. www.nutrition.org

153. Varady KA, Wang Y, Jones PJ. "Role of policosanols in theprevention and treatment of cardiovascular disease." Nutr Rev. 61,11:376-83, 2003. www.ilsi.org/publications/reviews.html

154. Menendez R et al. "Effects of policosanol treatment on thesusceptibility of low density lipoprotein (LDL) isolated from healthy volunteersto oxidative modification in vitro." Br J Clin Pharmacol. 50,3:255-62, 2000.

155. Castano G et al. "Effects of policosanol and lovastatin on lipidprofile and lipid peroxidation in patients with dyslipidemia associated withtype 2 diabetes mellitus." Int J Clin Pharmacol Res. 22, 3-4:89-99,2002.

156. Mas R et al. "Long-term effects of policosanl on obese patientswith Type II hypercholesterolemia." Asia Pac J Clin Nutr. 13,Suppl.:S102, 2004. www.healthyeatingclub.com/APJCN/ProcNutSoc/

157. Ackermann RT et al. "Garlic shows promise for improving somecardiovascular risk factors." Arch Intern Med. 161, 6:813-24, 2001. http://archinte.ama-assn.org

158. Ou CC. "Protective action on human LDL against oxidation andglycation by four organosulfur compounds derived from garlic." Lipids.38, 3:219-24, 2003. www.aocs.org

159. Morihara N et al. "Aged garlic extract enhances production ofnitric oxide." Life Sci. 71, 5:509-17, 2002. www.sciencedirect.com/science/journal/00243205

160. Budoff MJ et al. "Inhibiting progression of coronary calcificationusing Aged Garlic Extract in patients receiving statin therapy: a preliminarystudy." Prev Med. 39, 5:985-91, 2004. www.elsevier.com/locate/issn/0091-7435

161. Wang X et al. The hypolipidemic natural product Commiphora mukul andits component guggulsterone inhibit oxidative modification of LDL. Atherosclerosis.172, 2:239-46, 2004. http://www.sciencedirect.com/science/journal/00219150

162. Urizar NL and Moore DD. GUGULIPID: a natural cholesterol-loweringagent. Annu Rev Nutr. 23:303-13, 2003. http://arjournals.annualreviews.org/